Search research articles
Contact Us
Filters
Showing results (1-10 of 150) with videos related to
Page
of 15
Sort By:
Journal for Immunotherapy of Cancer
|
January 14, 2026
Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma
Bi-Cheng Wang
Oral Oncology
|
October 1, 2021
Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
March 21, 2025
Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
February 6, 2025
Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer-a prospective observation study
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
April 30, 2025
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
July 23, 2025
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk <i>et al</i>
Bi-Cheng Wang
Archives of Biochemistry and Biophysics
|
April 3, 2016
SAD phasing: History, current impact and future opportunities
John P Rose, Bi-Cheng Wang
Acta Crystallographica. Section D, Biological Crystallography
|
June 29, 2005
SGXPro: a parallel workflow engine enabling optimization of program performance and automation of structure determination
Zheng Qing Fu, John Rose, Bi Cheng Wang
Frontiers in Immunology
|
May 22, 2023
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
Bi-Cheng Wang, Chen Fu, Guo-He Lin
Toxins
|
September 18, 2014
Structural insights into Bacillus thuringiensis Cry, Cyt and parasporin toxins
Chengchen Xu, Bi-Cheng Wang, Ziniu Yu, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 150) with videos related to
Sort By:
Page
of 15
Journal for Immunotherapy of Cancer
|
January 14, 2026
Cadonilimab (mono anti-PD-1/CTLA-4 therapy) in advanced esophageal squamous cell carcinoma
Bi-Cheng Wang
Oral Oncology
|
October 1, 2021
Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
March 21, 2025
Letter to the editor: safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
February 6, 2025
Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer-a prospective observation study
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
April 30, 2025
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
Bi-Cheng Wang
Journal for Immunotherapy of Cancer
|
July 23, 2025
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk <i>et al</i>
Bi-Cheng Wang
Archives of Biochemistry and Biophysics
|
April 3, 2016
SAD phasing: History, current impact and future opportunities
John P Rose, Bi-Cheng Wang
Acta Crystallographica. Section D, Biological Crystallography
|
June 29, 2005
SGXPro: a parallel workflow engine enabling optimization of program performance and automation of structure determination
Zheng Qing Fu, John Rose, Bi Cheng Wang
Frontiers in Immunology
|
May 22, 2023
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
Bi-Cheng Wang, Chen Fu, Guo-He Lin
Toxins
|
September 18, 2014
Structural insights into Bacillus thuringiensis Cry, Cyt and parasporin toxins
Chengchen Xu, Bi-Cheng Wang, Ziniu Yu, et al.
Page
of 15